Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Multiple Myeloma 12Lymphoma, Non-Hodgkin 7Carcinoma, Non-Small-Cell Lung 5Lymphoma, Large B-Cell, Diffuse 4Breast Neoplasms 4Recurrence 3Melanoma 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Urinary Bladder Neoplasms 2Lymphoma, Follicular 2Cytokine Release Syndrome 2Craniopharyngioma 2Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

Temozolomide 19Magnetic Resonance Spectroscopy 15Specimen Handling 13Radiotherapy 13Radiation 9Biopsy 5pembrolizumab 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Bevacizumab 4vorasidenib 3trametinib 3Surgical Procedures, Operative 3Spinal Puncture 3tovorafenib 2dabrafenib 2Restraint, Physical 2Leukapheresis 2Ipilimumab 2Genetic Therapy 2Fluorodeoxyglucose F18 2Eflornithine 2Craniotomy 2Carboplatin 214-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene 2vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1tocilizumab 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × tocilizumab × 1 year × Clear all
NCT04729959 2026-04-01

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
59 enrolled
CNS

Astrocytoma, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡